The peak experience variable in DPT-assisted psychotherapy with cancer patients

Peak experiences—profound, memorable alterations of consciousness often described as involving unity, transcendence of time and space, and intense positive affect—have long intrigued philosophers and clinicians but their role in psychotherapy remains poorly characterised. Earlier research was largely theoretical or anecdotal; the discovery of LSD and related psychedelics provided tools that, when combined with attention to non‑pharmacological variables (set and setting), permit relatively reliable evocation of altered states in research contexts. The authors frame the peak experience in the specific, Maslow/Pahnke‑influenced sense of a unitive, ego‑transcendent state and note that its actual contribution to therapeutic change is not well established. This study therefore set out to examine two related questions: whether the occurrence of a peak experience during DPT‑assisted psychotherapy (referred to as DPT or OPT in the extracted text) is associated with greater short‑term therapeutic benefit for cancer patients, and which baseline or procedural factors predict the likelihood of experiencing a peak state. Chards and colleagues aimed to operationalise peak experience using established instruments and to compare clinical and observer‑rated outcomes between patients who did and did not report such experiences during a single DPT session embedded in a short‑term therapy programme.

The project was an open clinical study of DPT‑assisted psychotherapy in cancer patients; the extracted text does not indicate randomisation or a control arm. Thirty‑four subjects entered the protocol. The therapeutic procedure had three phases: preparatory psychotherapy (Phase I), the DPT administration day including the drug action period (Phase II), and post‑session integration therapy (Phase III). For 26 subjects the drug session was conducted as an inpatient in a private room at Sinai Hospital; eight received treatment as outpatients at the Maryland Psychiatric Research Center. All therapists who participated were male. Dosing was intramuscular DPT (referred to as OPT/DPT interchangeably in the extraction) in moderately high amounts; the reported dosage range was 75 to 127.5 mg, with a mean dose of 101.7 mg and a median/mode of 105 mg. Session duration during drug action ranged from about 4 to 10 hours, with a mean reported as approximately 6 hours. During drug action, environmental stimulation was minimised (sleep‑shade, stereophonic symphonic/choral music) and a therapist plus a trained nurse provided continuous interpersonal support. Integration therapy began the day after the session; the extracted text reports post‑session therapist time as "2'll hours" in the week following and an additional 2 hours spread over the next three weeks—the precise first figure is unclear in the extraction. Assessments included baseline psychological testing and independent ratings. Prior to the first therapist meeting subjects completed the Personal Orientation Inventory (POI) and an abbreviated MMPI (Mini‑Mult). Two male psychiatric social workers, blind to the study’s specific focus on peak experiences, provided independent ratings using the Brief Psychiatric Rating Scale (BPRS) at baseline, the day before DPT administration, and one week after. The primary instrument to identify peak experiences was the Psychdelic Experience Questionnaire (PEQ), a 100‑item measure with 43 core items mapping the six categories that define the peak experience; a score of 60% or greater on the core items was taken (following Pahnke) to indicate a peak experience. A therapist‑completed Peak Experience Rating Form (PERF) scored each of the six categories on a 0–4 scale (total possible 24); a PERF total of 15 was used to classify three subjects who failed to complete the PEQ. Statistical approaches reported in the extraction included independent t‑tests, dependent t‑tests, and analysis of covariance (ANCOVA) using baseline measures as covariates.

Sample classification and basic descriptors: Using the PEQ/PERF criteria, 15 subjects were classified as having had a peak experience (peakers) and 19 as non‑peakers; three subjects without PEQ data were classed by PERF. The two groups differed clearly on the intensity of the six content categories that define peak experience. Baseline comparisons and predictors: On baseline POI testing, significant differences between groups were found on two scales—Time Competency and Existentiality—where peakers scored lower than non‑peakers, suggesting less ability to "live in the present" and less flexibility in value application prior to therapy. No group differences emerged for sex, race, marital status or years of education. Age was associated with likelihood of a peak experience: subjects aged 30–50 were significantly more likely to be peakers than those outside that range (χ2 = 9.28, P < .05). Stage of disease showed an association such that peak experiences were more probable in Stage I or Stage III than in Stage II (χ2 = 5.91, P < .02); of 20 subjects in Stage II, 14 did not have peak experiences. On the day prior to DPT, independent BPRS ratings indicated differential states: non‑peakers manifested increased anxiety relative to baseline (dependent t, df = 17, t = 2.13, P < .05), whereas peakers showed a decrease in hostility (dependent t, df = 11, t = 2.73, P < .01). ANCOVA controlling for baseline yielded significant group differences on BPRS Anxiety, Tension and Hostility scales (F(1,28) ≈ 4.7–4.94, P < .05), indicating that non‑peakers were judged more anxious, tense and hostile on the day before DPT. Procedural variables: The mean hours of preparatory therapy were 10.8 for peakers and 9.2 for non‑peakers; this difference did not reach statistical significance. Mean DPT dose was 99.0 mg for peakers and 103.8 mg for non‑peakers, a small non‑significant difference. No notable differences were found in peaker/non‑peaker proportions across the six therapists who delivered treatment. Outcomes: Patient self‑reports showed greater increases in self‑actualisation from pre‑therapy to one week post‑DPT for peakers than for non‑peakers (POI analyses reported significant effects; Mini‑Mult ANCOVA produced no significant differential effects in the extracted text). Independent observer ratings (average inter‑rater reliability r = 0.62) did not detect significant pre‑to‑post change for either group on the BPRS when tests were calculated separately; likewise ANCOVA on BPRS data yielded no significant differential results in those analyses. The authors highlight specific POI improvements for peakers in "Capacity for Intimate Contact" and "Existentiality," interpreted as increased interpersonal openness and greater tolerance of individual differences with family members. Other observations: Non‑peakers often showed marked anxiety on the day prior to DPT that tended to resolve one week after administration (dependent t, df = 17, t = 2.78, P < .02). Some non‑peakers reported personally meaningful experiences during drug action that did not meet the study’s unitive definition of peak experience; an example given is a visionary religious sequence that lacked the sense of ego‑transcendence required by the operational definition. No subjects appeared to have been physically or psychologically harmed by participation, and the authors note that additional therapy or further drug sessions might have produced peaks in some non‑peakers.

Chards and colleagues interpret their findings as suggesting that peak experiences may constitute an intrinsic element of effective psychotherapy for some patients, with a correlation between such experiences and more rapid therapeutic progress in the short‑term psychotherapy of cancer patients. They emphasise that peakers showed larger magnitudes of clinical change on self‑report measures—particularly in interpersonal openness and existential attitude—while independent blind raters did not confirm these therapist and self‑report impressions. The investigators consider several explanations for the discrepancy between observer ratings and clinician/patient reports. One methodological factor is that independent raters had been instructed not to question patients about the content of their drug‑period experiences, a safeguard intended to reduce bias that may inadvertently have inhibited patient disclosure and thus blunted observer detection of change. The authors also note that several POI scales are interrelated, which complicates interpretation of multiple significant findings on that instrument. They suggest that peak experience occurrence was associated with prior therapeutic engagement and psychological readiness: peakers often appeared highly motivated, more engaged in preparatory work, and better able to confront affective material, whereas non‑peakers in some cases remained more defensive or less ready to relinquish control. Limitations acknowledged in the extracted text include the absence of an untreated control group, which prevents firm attribution of observed change to the psychotherapy or DPT intervention alone. The unpredictable, non‑random occurrence of peak experiences means subjects were not randomly assigned to groups; however, the authors point out that occurrence could not be predicted in advance. Additional methodological cautions noted are the potential influence of interrelated test scales and the unclear effect of instructing raters to avoid probing experiential content. Clinical implications discussed by the authors include the importance of integration work—therapeutic assimilation of insights into everyday self‑concept and worldview may determine the lasting relevance of a peak experience—and the suggestion that, for some patients, multiple sessions and a more extended therapeutic relationship may be required before a peak state can be safely and reliably evoked and integrated. The authors call for further research to clarify the causal role of peak experiences in therapeutic change and to delineate prerequisites and optimal procedures for facilitating and integrating such experiences.